zoledronic acid


Novartis Pharma


X3 Lifescience
Concise Prescribing Info
Zoledronic acid
Prevention of skeletal-related events (pathological fractures, spinal compression, bone radiation or surgery, or tumour-induced hypercalcaemia) in patients w/ advanced bone malignancies. Hypercalcaemia of malignancy (HCM).
Dosage/Direction for Use
Adult & elderly Prevention of skeletal-related events in patient w/ advanced bone malignancies 4 mg as single IV infusion in no <15 min every 3-4 wk w/ PO Ca supplement 500 mg & vit D 400 IU daily. HCM 4 mg as single IV infusion in no <15 min. Renal impairment CrCl >60 mL/min 4 mg, 50-60 mL/min 3.5 mg, 40-49 mL/min 3.3 mg, 30-39 mL/min 3 mg.
Hypersensitivity to zoledronic acid or other bisphosphonates. Pregnancy & lactation.
Special Precautions
Osteonecrosis of the jaw (ONJ), external auditory canal & other anatomical sites eg, hip & femur; atypical subtrochanteric & diaphyseal femoral fractures; bone, joint &/or muscle pain. Avoid overhydration in patients at risk of cardiac failure. Correct hypocalcaemia prior to therapy; ensure adequate Ca & vit D supplementation during therapy. Monitor serum Ca, phosphate, Mg & creatinine levels during therapy; renal function in untreated hypercalcemia patients. Ensure adequate hydration prior to administration. Avoid invasive dental procedures during treatment. Maintain good oral hygiene & perform dental exam w/ preventive dentistry prior to treatment. Not to be given concomitantly w/ other bisphosphonates. Concomitant use w/ chemotherapy, corticosteroids, other hypocalcaemia-causing drugs. Not recommended in severe renal impairment. Hepatic impairment. Avoid pregnancy in women of childbearing potential. Not to be used during pregnancy & lactation.
Adverse Reactions
Hypophosphataemia. Anaemia; headache, paraesthesia; sleep disorder; conjunctivitis; nausea, vomiting, decreased appetite, constipation; hyperhidrosis; bone pain, myalgia, arthralgia, generalized body pain, joint stiffness; HTN; renal impairment; acute phase reaction, pyrexia, flu-like illness, peripheral oedema, asthenia; increased blood creatinine & urea, hypocalcaemia.
Drug Interactions
Additive effect w/ aminoglycosides, calcitonin, loop diuretics. Increased incidence of ONJ w/ anti-angiogenic drugs. Other potentially nephrotoxic drugs, thalidomide. Not to be mixed w/ Ca, other infusion soln or other divalent cation-containing infusion soln eg, lactated Ringer's soln.
MIMS Class
Agents Affecting Bone Metabolism
ATC Classification
M05BA08 - zoledronic acid ; Belongs to the class of bisphosphonates. Used in the treatment of bone diseases.
Zometa infusion conc 4 mg/5 mL
10 × 1's;1's;4 × 1's
Zometa soln for infusion 4 mg/100 mL
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in